Cannabis for PTSD: A Medical Guide for Australian Patients

Last updated: January 2026 | Reviewed by a registered Australian medical practitioner

This guide is for Australian adults living with post-traumatic stress disorder (PTSD) who want to understand whether medicinal cannabis — including CBD oil and THC-based products — may play a role in managing their symptoms. In short: medicinal cannabis is a legal, clinician-prescribed treatment option in Australia for some people with PTSD, but it is not a first-line therapy, results vary between individuals, and access requires a prescription from an authorised medical practitioner. This page explains the evidence, the diagnostic context, and what to expect if you pursue this treatment pathway.

What Is PTSD and How Is It Diagnosed?

Post-traumatic stress disorder is a mental health condition that can develop after exposure to a traumatic event, such as assault, combat, accident, natural disaster, or childhood abuse. According to the Australian Institute of Health and Welfare, approximately 12% of Australians will experience PTSD at some point in their lives, with higher rates among emergency service workers, veterans, and survivors of interpersonal violence.

In Australia, clinicians use criteria from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) to diagnose PTSD. A diagnosis requires all of the following symptom clusters to be present for more than one month and to cause significant functional impairment:

• Re-experiencing: Intrusive memories, flashbacks, nightmares, or intense distress when reminded of the trauma
• Avoidance: Actively avoiding thoughts, feelings, people, or places associated with the trauma
• Negative alterations in cognition and mood: Persistent negative beliefs, emotional numbing, feelings of detachment, or inability to experience positive emotions
• Hyperarousal: Hypervigilance, exaggerated startle response, difficulty sleeping, irritability, or concentration problems

PTSD frequently co-occurs with depression, substance use disorders, and chronic pain, which can complicate treatment selection.

What Are the Standard Treatments for PTSD in Australia?

Australian clinical guidelines, including those from Phoenix Australia — Centre for Posttraumatic Mental Health, recommend trauma-focused psychological therapies as the primary treatment for PTSD. These include:

• Trauma-Focused Cognitive Behavioural Therapy (TF-CBT)
• Prolonged Exposure (PE) therapy
• Eye Movement Desensitisation and Reprocessing (EMDR)
• Cognitive Processing Therapy (CPT)

When medication is used, SSRIs such as sertraline and paroxetine are the most commonly prescribed, though evidence for pharmacotherapy in PTSD is considered moderate at best. A significant proportion of patients do not achieve adequate symptom relief through first-line treatments, which is one reason alternative and adjunctive therapies — including medicinal cannabis — have attracted clinical interest.

How Might Cannabis Interact With the Endocannabinoid System to Affect PTSD?

The endocannabinoid system (ECS) is a signalling network found throughout the central and peripheral nervous systems. It comprises endogenous cannabinoids (primarily anandamide and 2-AG), cannabinoid receptors (CB1 and CB2), and enzymes that synthesise and degrade these compounds. The ECS plays a documented role in regulating fear learning, memory consolidation, anxiety responses, and sleep — all processes that are dysregulated in PTSD.

Research has found that people with PTSD show reduced levels of anandamide and altered CB1 receptor availability in brain regions involved in fear processing, including the amygdala and prefrontal cortex. Plant-derived cannabinoids interact with this system in the following general ways:

• THC (tetrahydrocannabinol): A partial agonist at CB1 receptors. At therapeutic doses, THC may reduce nightmares, improve sleep quality, and blunt the re-experiencing of traumatic memories. At higher doses, THC can increase anxiety and paranoia, particularly in individuals with no prior tolerance.
• CBD (cannabidiol): Does not bind directly to CB1 receptors with high affinity but modulates the ECS through multiple indirect mechanisms, including inhibition of anandamide breakdown. CBD has demonstrated anxiolytic (anxiety-reducing) and fear extinction-facilitating properties in preclinical and some human studies.

It is important to note that most mechanistic understanding of cannabis in PTSD comes from preclinical models and small human trials. The evidence base is growing but remains insufficient to draw definitive clinical conclusions.

What Does the Current Evidence Say About Cannabis for PTSD?

The research landscape as of 2026 includes a mix of observational studies, small randomised controlled trials, and retrospective chart reviews. Key findings include:

In the Australian context, the Therapeutic Goods Administration (TGA) acknowledges that PTSD is one of the more common conditions for which medicinal cannabis is prescribed via the Special Access Scheme. However, the TGA has not formally approved any cannabis product specifically for PTSD, meaning prescriptions remain off-label under either the SAS-B pathway or via an Authorised Prescriber.

What Are the Potential Benefits of Medicinal Cannabis for PTSD?

Based on current evidence, the symptom areas where medicinal cannabis shows the most clinical interest — though not proven efficacy — include:

• Reducing the frequency and severity of trauma-related nightmares
• Improving sleep onset and maintenance
• Reducing hyperarousal and generalised anxiety between trauma reminders
• Facilitating engagement with psychological therapies by reducing baseline distress
• Providing an alternative for patients who have not responded to or cannot tolerate SSRIs

These are areas of ongoing research interest, not confirmed treatment outcomes. Individual responses vary considerably depending on product formulation, dosing, prior cannabis exposure, and co-occurring conditions.

What Are the Risks and Side Effects?

Medicinal cannabis carries risks that must be weighed against potential benefits, particularly in a population where anxiety, dissociation, and substance use disorders are common comorbidities.

• THC-related: Acute anxiety, paranoia, cognitive impairment, psychomotor slowing, increased heart rate, and dependency risk with prolonged use. Higher doses or high-THC products carry greater risk.
• CBD-related: Generally well tolerated. Potential interactions with other medications (particularly those metabolised by cytochrome P450 enzymes, including some antidepressants and anticonvulsants). High doses may cause diarrhoea, fatigue, or changes in appetite.
• PTSD-specific concern: Cannabis use can be a mechanism of avoidance in PTSD. If used to suppress emotional processing rather than as an adjunct to therapy, it may interfere with psychological treatment goals. This is a significant consideration for prescribing clinicians.
• Driving and work: THC-containing products impair driving ability. In all Australian states and territories, it is illegal to drive with THC detectable in oral fluid, regardless of whether it was prescribed. This has practical consequences for employment in safety-sensitive roles.

How Do Australians Access Medicinal Cannabis for PTSD?

Medicinal cannabis is legal at the federal level in Australia under a prescription framework regulated by the TGA. The main access pathways are:

• Special Access Scheme Category B (SAS-B): Any registered medical practitioner can apply to the TGA for approval to prescribe an unapproved therapeutic good (including most medicinal cannabis products) for a specific patient. Approvals are typically granted within 48 hours for straightforward applications.
• Authorised Prescriber (AP) scheme: A doctor who has been approved by the TGA and an ethics committee to prescribe a specific cannabis product to a class of patients without requiring individual applications.
• State and territory regulations: While federal law governs the TGA framework, individual states have their own controlled substances legislation. Queensland, New South Wales, Victoria, and other states permit medicinal cannabis under their respective frameworks, but patients should confirm current rules in their jurisdiction, as regulations can change.

To access medicinal cannabis, a patient must be assessed by a doctor who determines it is clinically appropriate. Many specialist medicinal cannabis clinics operate across Australia, and some general practitioners are also authorised prescribers or willing to apply under SAS-B. Cannabis products cannot be purchased without a valid prescription.

Should You Raise Cannabis With Your Mental Health Clinician?

If you are already receiving care for PTSD from a psychiatrist, psychologist, or GP, discussing medicinal cannabis with your treating team before pursuing a separate prescription is advisable. A coordinated approach reduces the risk of drug interactions, avoidance-based use patterns, and interference with psychological treatment. If your current clinician is not familiar with medicinal cannabis prescribing, a referral to a specialist clinic does not require you to change your existing care.

Frequently Asked Questions

Is CBD oil legal in Australia for PTSD?

Low-dose CBD products (up to 150mg per day) were rescheduled to Schedule 3 in 2021, meaning a pharmacist can supply them without a prescription, though few such products are currently available over the counter. Higher-dose CBD and any THC-containing product requires a prescription through the TGA access pathways. Neither category constitutes a formally approved PTSD treatment — prescribing is off-label.

Will medicinal cannabis make my PTSD worse?

It may, in some circumstances. High-THC products can acutely increase anxiety and paranoia, and cannabis use that functions as emotional avoidance may hinder trauma processing. Individual risk depends on factors including prior cannabis experience, the specific product and dose, and whether use is coordinated with psychological care. This is why clinical assessment before starting treatment matters.

Can veterans access medicinal cannabis for PTSD through the DVA?

As of early 2026, the Department of Veterans' Affairs (DVA) does not routinely fund medicinal cannabis as a covered treatment. Some veterans access it through separate self-funded prescriptions. DVA-funded mental health care remains focused on evidence-based psychological therapies and approved pharmacotherapy. Veterans should contact DVA directly and consult their treating clinician for the most current funding guidance.

How long does it take for medicinal cannabis to work for PTSD symptoms?

This varies by product type, delivery method, and the symptom being targeted. Inhaled or sublingual products may produce effects within minutes, while oral formulations can take one to two hours. Sustained symptom improvement — such as reduced nightmare frequency — may take several weeks of consistent use at a stable dose. Your prescribing doctor will typically review response at four to eight weeks.

Does medicinal cannabis replace psychological therapy for PTSD?

No. Australian clinical guidelines position trauma-focused psychological therapies as the primary treatment for PTSD. Medicinal cannabis, where used, is considered an adjunctive option for symptom management, not a standalone treatment. There is no current evidence that cannabis addresses the underlying trauma processing that psychological therapies are designed to facilitate.

Sources

• Therapeutic Goods Administration — Medicinal Cannabis: tga.gov.au/products/unapproved-therapeutic-goods/medicinal-cannabis-products
• Phoenix Australia — Australian Guidelines for the Treatment of Acute Stress Disorder and PTSD: phoenixaustralia.org/resources/ptsd-guidelines
• Australian Institute of Health and Welfare — Mental Health: aihw.gov.au/mental-health
• Bonn-Miller et al. (2021) — Preliminary investigation of the impact of different cannabis products on PTSD symptom severity, Psychopharmacology: doi.org/10.1007/s00213-021-05875-6
• National Centre for Complementary and Integrative Health — Cannabis and Cannabinoids: nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
• Department of Veterans' Affairs Australia — Mental Health Support: dva.gov.au/health-and-treatment/health-and-wellbeing/mental-health